United Therapeutics (UTHR) Other Non-Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $214.0 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $214.0 million, down 0.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $214.0 million (down 0.56% YoY), and the FY2025 annual result was $223.2 million, up 22.7% from the prior year.
• Other Non-Current Liabilities came in at $214.0 million for Q1 2026 at United Therapeutics, down from $223.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $223.2 million in Q4 2025 to a low of $67.4 million in Q3 2023.
• The 5-year median for Other Non-Current Liabilities is $103.5 million (2022), against an average of $137.1 million.
• Across the five-year window, Other Non-Current Liabilities sank 34.88% in 2023 and surged 133.8% in 2024, its largest moves.
• United Therapeutics' Other Non-Current Liabilities stood at $104.6 million in 2022, then fell by 25.62% to $77.8 million in 2023, then soared by 133.8% to $181.9 million in 2024, then gained by 22.7% to $223.2 million in 2025, then decreased by 4.12% to $214.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $214.0 million (Q1 2026), $223.2 million (Q4 2025), and $214.6 million (Q3 2025), per Business Quant data.